• Medientyp: E-Artikel
  • Titel: Incidence and clinical outcome of Coronavirus disease 2019 in a cohort of 11,560 Brazilian patients with multiple sclerosis
  • Beteiligte: Ferreira, Lis Campos; Sousa, Nise Alessandra de Carvalho; Ferreira, Maria Lucia Brito; Dias-Carneiro, Rafael Paternò Castello; Mendes, Maria Fernanda; Piccolo, Ana Claudia; Thomaz, Rodrigo Barbosa; Vasconcelos, Claudia Cristina Ferreira; Alves-Leon, Soniza Vieira; Santos, Gutemberg Augusto Cruz dos; Pereira, Valéria Coelho Santa Rita; de Oliveira, Enedina Maria Lobato; Pereira, Samira Luisa Apóstolos; Boaventura, Mateus; Disserol, Caio César Diniz; Neto, Herval Ribeiro Soares; Martins, Gabriela Joca; ďAlmeida, José Arthur; Pitombeira, Milena S.; Mendes, Lucas Silvestre; Dourado, Mario Emilio Teixeira; de Oliveira, Bianca Etelvina Santos; Guerra, Davi Veloso; Machado, Maria Íris de Morais; [...]
  • Erschienen: SAGE Publications, 2021
  • Erschienen in: Multiple Sclerosis Journal, 27 (2021) 10, Seite 1615-1619
  • Sprache: Englisch
  • DOI: 10.1177/1352458520978354
  • ISSN: 1352-4585; 1477-0970
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:sec><jats:title>Background:</jats:title><jats:p> Little information is available regarding the incidence and clinical outcome of the SARS-CoV2 infection in patients with multiple sclerosis (pwMS). </jats:p></jats:sec><jats:sec><jats:title>Objective:</jats:title><jats:p> To determine the incidence, clinical outcome, and impact of COVID-19 on pwMS. </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> This observational study was prospectively performed on a cohort of pwMS ( N = 11,560) followed up by 47 out of 51 Brazilian MS referral centers that registered pwMS with COVID-19 at the REDONE platform from 13 March to 4 June 2020. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> The incidence of COVID-19 for pwMS patients was 27.7/10,000 patients and for the general population was 29.2/10,000 inhabitants. A total of 94 (77 women) pwMS patients, aged 40 ± 10.25 years, presenting 9.9 ± 8.6 years of MS disease duration, developed the COVID-19, most of them (87%) exhibited the mild form of the disease. Eighty (96%) patients maintained the use of MS disease-modifying treatment (DMT) during COVID-19 pandemic and 14 patients were not in use of DMTs. </jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p> Incidence of COVID-19 in Brazilian pwMS was not different from those observed for the general Brazilian population. Most pwMS exhibited mild COVID-19, despite the maintenance of the underlying MS treatment. </jats:p></jats:sec>